7 unknown, 4 withdrawn, 3 completed, 2 terminated. 8 Phase 2, 5 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 4, Withdrawn 2, Completed 1, Terminated 1 |
| Phase 1 | 5 | Unknown 2, Withdrawn 2, Completed 1 |
| Phase 3 | 2 | Suspended 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Immunization, Passive: new trials by email Literature Review of Immunization, Passive trials Research Report on Immunization, Passive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer immunity therapy - Non Small Cell Lung Cancer | Unknown | Yongchang Zhang | 186 | 2023-01-01 | 2024-09-19 | |
| Effect of Pressotherapy on Health Outcomes in Patients With Chronic Stroke GMove Suit, Normal therapy - Stroke | Not applicable | Completed | University of Winchester | 31 | 2022-04-01 | 2024-03-15 |
| Safety and Effectiveness of an Immunobiological Drug in CoViD-19 Anti-SARS-CoV-2, Placebo - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Phase 2 / Phase 3 | Unknown | Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran | 200 | 2021-06-01 | 2021-09-17 |
| Convalescent Plasma Therapy in Severe COVID-19 Infection Convalescent plasma - Covid19, Convalescence | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 20 | 2020-05-20 | 2020-05-27 |
| Convalescent Plasma Therapy for COVID-19 Patients convalescent plasma - SARS-CoV Infection | Early Phase 1 | Unknown | Lahore General Hospital | 20 | 2020-05-01 | 2020-12-08 |
| Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series Convalescent Plasma Therapy - Infectious Disease | Completed | Maranatha Christian University | 8 | 2020-04-01 | 2021-09-16 | |
| Intravenous Immunoglobulin for Acute Intracranial Hemorrhage Immunoglobulin Therapy, Standard management - Intracranial Hemorrhage, Hypertensive | Phase 2 | Unknown | Wei Wang | 60 | 2016-06-01 | 2016-05-25 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Aldesleukin, Antibody Therapy, Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 2 | 2015-12-01 | 2023-05-15 |
| Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI) Immunoglobulin Therapy - Primary Immune Deficiency Disorder | Terminated | BriovaRx Infusion Services | 1500 | 2013-06-01 | 2019-08-07 | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-08-01 | 2007-08-14 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma cisplatin, cytarabine, etoposide - AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2006-02-01 | 2016-02-03 | |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors monoclonal antibody anti-anb3 integrin, anti-cytokine therapy, antiangiogenesis therapy - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2002-02-01 | 2014-01-16 | |
| Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer antibody therapy, biological therapy, muromonab-CD3 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Unknown | St. Vincent Medical Center - Los Angeles | 1991-06-01 | 2013-11-06 | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma bortezomib, rituximab, antibody therapy - Lymphoma | Phase 2 | Terminated | University of Virginia | 46 | 2008-01-28 | |
| BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia BL22 immunotoxin, antibody therapy, biological response modifier therapy - Leukemia, Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 | ||
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer bevacizumab, gemcitabine hydrochloride, adjuvant therapy - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 | ||
| GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 3 | Suspended | Favrille | 480 | 2013-12-18 |
COVID-19 (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Pancreatic Neoplasms (2) · Agammaglobulinemia (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cerebral Hemorrhage (1)
Barbara Ann Karmanos Cancer Institute (2) · National Cancer Institute (NCI) (2) · AIDS Malignancy Consortium (1) · Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · BriovaRx Infusion Services (1) · Cambridge Antibody Technology (1) · Favrille (1) · Lahore General Hospital (1) · Maranatha Christian University (1) · St. Vincent Medical Center - Los Angeles (1) · University of Virginia (1) · University of Winchester (1) · Wei Wang (1) · Yongchang Zhang (1)
United States (7) · China (2) · Argentina (1) · Bangladesh (1) · Indonesia (1) · Pakistan (1) · Poland (1) · United Kingdom (1)
Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Anthony Shields (1) · Charles L. Wiseman, MD, FACP (1) · Guillermo A Keller, PhD (1) · John Densmore, MD (1) · John F. Bender, PharmD (1) · Mohammad S Rahman, MPhil; FCPS (1) · Muhammad Irfan Malik, FCPS (1) · Patricia LoRusso, DO (1) · Richard E. Royal, MD, FACS (1) · Robert Kreitman, MD (1) · Simon Jobson, PhD (1) · Theresia M Rahardjo, Dr (1) · Wei Wang, Doctor (1)
PMID 15616839, PMID 17855683, PMID 32167489, PMID 32219428, PMID 32253318, PMID 32254064, PMID 32634589, PMID 32694043, PMID 32792417, PMID 32934372, PMID 32939319, PMID 33106167, PMID 33406353, PMID 33621405
P30CA022453 (1)